Treatment And Prognosis With Thalidomide In Multiple Myeloma Based on Karyotyping And Gene Expression Profiling
AssigneeBoard of Trustees of the University of Arkansas
InventorsJohn D. Shaughnessy, JR., Bart Barlogie
Life of this patent
Estimating the term…
Abstract
The present invention provides a method treating a myeloma patient by administering one or more of thalidomide, a Total Therapy 2 regimen, an interleukin-6 signaling suppressor, an interleukin-6R signaling suppressor, an IGF1 signaling suppressor, an IGF1 R signaling suppressor, shRNA or other modulators of gene expression. Also, provided are methods for predicting outcome of a treatment for an individual having a cancer, e.g., myeloma, by performing one or more of karyotyping or expression profiling of chromosomes 1 and 13 or expression level measurement of IL-6R.
Claims21
1-33. (canceled)
A method of identifying a multiple myeloma patient as being responsive to a treatment regimen comprising thalidomide, comprising testing the level of gene expression of interleukin-6 receptor (IL-6R) in plasma cells isolated from a multiple myeloma patient determined to have gene expression profiling (GEP)-defined low-risk multiple myeloma, wherein the presence of a normal IL-6R gene expression level, relative to a suitable control, indicates that the subject will be responsive to a treatment regimen comprising thalidomide.
A method of predicting the presence of a cytogenetic abnormality on both chromosome 1 and chromosome 13 in a subject having multiple myeloma, comprising testing the level of gene expression of IL6-R in plasma cells isolated from the subject, wherein an elevated IL6-R gene expression level, relative to a suitable control, indicates that the subject has a cytogenetic abnormality on both chromosome 1 and chromosome 13.
Dependencies are inferred from the claim text.